Ticker brief
SNY SANOFI-ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$41.60
1 day
-0.9%
14 days
+3.8%
mkt cap
$103.3B
signals 14d
13
authors 14d
11
crowd 14d
+0.1σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 30% rich · 92 pctile own 1y | IV/HV 1.22× |
| Skew — 25Δ RR 30d | -0.005 74 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | -0.01 normal | 5-session Δ -0.00 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-07-10 (z=2.1) |
| Next earnings | 2026-10-30 (proj) | in 4d |
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-15 · now +0.02 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.87 | 3 | -0.20 |
| @VistaPResearch | C | · | 1 | +0.10 |
| @buzztickr | C | · | 1 | +0.00 |
| @bahabreaking | C | -0.42 | 1 | +0.20 |
| @robertojirusta | C | -0.38 | 1 | +0.30 |
| @fwpharma | B | -1.91 | 1 | -0.15 |
| @OpenOutcrier | C | · | 1 | +0.20 |
| @zohmbastic | C | -2.94 | 1 | +0.00 |
| @CHItrader | B | -0.22 | 1 | -0.20 |
| @DrAhmadAlsabban | C | -0.05 | 1 | +0.45 |
| @CrweWorld | C | · | 1 | +0.15 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @CrweWorld | +0.15 | Sanofi and pCPA sign a letter of intent covering Dupixent across four indications | +3.3% | tweet ↗ |
| 2026-10-15 | @DrAhmadAlsabban | +0.45 | Updates three existing positions, considering selling KMB, adding SNY and holding or selling O. | +3.3% | tweet ↗ |
| 2026-10-15 | @CHItrader | -0.20 | Sanofi must correct statements about a rival flu vaccine under an EU antitrust agreement. | +3.3% | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | -0.30 | Expects small/mid-cap biotech to catch up as large pharma faces revenue cliffs and increasing need for external assets. | +3.3% | tweet ↗ |
| 2026-10-15 | @zohmbastic | +0.00 | Notes an RXRX recovery while also tagging SNY without explaining its role. | +3.3% | tweet ↗ |
| 2026-10-14 | @OpenOutcrier | +0.20 | Sanofi avoided a fine after the EU accepted its offer concerning rival-vaccine disparagement. | +4.6% | tweet ↗ |
| 2026-10-14 | @fwpharma | -0.15 | Sanofi reportedly committed to remedy harm from a campaign against a rival flu shot. | +4.6% | tweet ↗ |
| 2026-10-14 | @robertojirusta | +0.30 | The EU accepted Sanofi's antitrust commitments. | +4.6% | tweet ↗ |
| 2026-10-14 | @bahabreaking | +0.20 | Reports EU acceptance of Sanofi's antitrust commitments. | +4.6% | tweet ↗ |
| 2026-10-13 | @buzztickr | +0.00 | Phase 3 clinical readout is scheduled for tomorrow | +6.3% | tweet ↗ |
| 2026-10-12 | @bioinvestor24 | -0.45 | Criticizes BMY's prior deals and warns management has a short window before potential collapse. | +4.7% | tweet ↗ |
| 2026-10-11 | @bioinvestor24 | +0.15 | Says MRK needs a new management team before its outcomes worsen. | +3.8% | tweet ↗ |
| 2026-10-07 | @VistaPResearch | +0.10 | Reports Sanofi up 0.91% to $39.92. | +3.5% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.